AxoGen Investor Relations Material
Latest events
Q3 2024
AxoGen
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from AxoGen Inc
Access all reports
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for peripheral nerve injury. It provides Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector that is a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector that is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. The company also offers Avive Soft Tissue Membrane that is a processed human umbilical cord membrane used as a resorbable barrier to separate tissues in repair or reconstruction procedures; and AcroVal Neurosensory & Motor Testing System.
Key slides for AxoGen Inc
Q3 2024
AxoGen Inc
Q3 2024
AxoGen Inc
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
AXGN
Country
🇺🇸 United States